HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” NASDAQ: TARO) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for its patent application on the use of the Company’s proprietary, non-sedating barbiturate compounds in the treatment of essential tremor and Parkinson’s disease. The patent will expire in June 2025. It is estimated that more than six million Americans suffer from these two conditions.
